Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer

被引：0
|
作者：
Toffart, A. -C. [1 ,2 ]
Sakhri, L. [1 ,2 ]
Moro-Sibilot, D. [1 ,2 ]
机构：
[1] Ctr Hosp Univ A Michallon, UM Oncol Thorac, F-38043 Grenoble 9, France
[2] Univ Grenoble 1, Inst A Bonniot, INSERM, U823, Grenoble, France
来源：
REVUE DE PNEUMOLOGIE CLINIQUE | 2013年 / 69卷 / 02期
关键词：
EML4-ALK; Lung cancer; Crizotinib; Targeted therapy; Never smoker; Adenocarcinoma; EML4-ALK FUSION GENE; KINASE INHIBITOR; RESISTANCE; REARRANGEMENT; MUTATIONS; EFFICACY; MET; NPM;
D O I：
10.1016/j.pneumo.2012.11.010
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Crizotinib is a small orally-administered ALK inhibitor for patients with non-small cell lung cancer with EML4-ALK rearrangement (echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase). This fusion gene is detected with a break apart fluorescence in situ hybridization (FISH) assay. Phase I to III trials have shown an interesting disease control rate and acceptable tolerability. Crizotinib is available in France under temporary use authorization. New potentially effective therapeutics in ALK-positive NSCLC are being developed. (C) 2013 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：111 / 116
页数：6
相关论文
共 50 条
  • [41] FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib
    Larkins, Erin
    Blumenthal, Gideon M.
    Chen, Huanyu
    He, Kun
    Agarwal, Rajiv
    Gieser, Gerlie
    Stephens, Olen
    Zahalka, Eias
    Ringgold, Kimberly
    Helms, Whitney
    Shord, Stacy
    Yu, Jingyu
    Zhao, Hong
    Davis, Gina
    McKee, Amye E.
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2016, 22 (21) : 5171 - 5176
  • [42] Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
    Peter N. Morcos
    Eveline Nueesch
    Felix Jaminion
    Elena Guerini
    Joy C. Hsu
    Walter Bordogna
    Bogdana Balas
    Francois Mercier
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 129 - 138
  • [43] Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients
    Edmond Bendaly
    Anand A. Dalal
    Kenneth Culver
    Philip Galebach
    Iryna Bocharova
    Rebekah Foster
    Medha Sasane
    Alexander R. Macalalad
    Annie Guérin
    Advances in Therapy, 2017, 34 : 1673 - 1685
  • [44] From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
    Pirker, Robert
    Filipits, Martin
    ESMO OPEN, 2019, 4 (05)
  • [45] Crizotinib in ALK-positive lung cancer
    Girard, Nicolas
    LANCET ONCOLOGY, 2012, 13 (10): : 962 - 963
  • [46] Clinical Outcomes of Crizotinib in Real-World Practice Settings for Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer
    Davis, K. L.
    Lenz, C.
    Houghton, K.
    Kaye, J. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 238 - 239
  • [47] Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
    Shaw, Alice T.
    Kim, Dong-Wan
    Nakagawa, Kazuhiko
    Seto, Takashi
    Crino, Lucio
    Ahn, Myung-Ju
    De Pas, Tommaso
    Besse, Benjamin
    Solomon, Benjamin J.
    Blackhall, Fiona
    Wu, Yi-Long
    Thomas, Michael
    O'Byrne, Kenneth J.
    Moro-Sibilot, Denis
    Camidge, D. Ross
    Mok, Tony
    Hirsh, Vera
    Riely, Gregory J.
    Iyer, Shrividya
    Tassell, Vanessa
    Polli, Anna
    Wilner, Keith D.
    Jaenne, Pasi A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (25): : 2385 - 2394
  • [48] Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    Thibault, Constance
    Teixeira, Luis
    ONCOLOGIE, 2013, 15 (09) : 494 - 495
  • [49] Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
    Peters, Solange
    Camidge, D. Ross
    Shaw, Alice T.
    Gadgeel, Shirish
    Ahn, Jin S.
    Kim, Dong-Wan
    Ou, Sai-Hong I.
    Perol, Maurice
    Dziadziuszko, Rafal
    Rosell, Rafael
    Zeaiter, Ali
    Mitry, Emmanuel
    Golding, Sophie
    Balas, Bogdana
    Noe, Johannes
    Morcos, Peter N.
    Mok, Tony
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09): : 829 - 838
  • [50] ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer
    Mc Leer, A.
    Duruisseaux, M.
    Pinsolle, J.
    Dubourg, S.
    Mondet, J.
    Phillips-Houlbracq, M.
    Magnat, N.
    Faure, J.
    Chatagnon, A.
    de Fraipont, F.
    Levra, M. Giaj
    Toffart, A. C.
    Ferretti, G.
    Brambilla, E.
    Hainaut, P.
    Moro-Sibilot, D.
    Lantuejoul, S.
    ANNALS OF ONCOLOGY, 2017, 28
12345